Total Payments
$39,063
2024 Payments
$11,626
Companies
12
Transactions
59
Medicare Patients
383
Medicare Billing
$63,308
Payment Breakdown by Category
Consulting$31,671 (81.1%)
Research$4,150 (10.6%)
Travel$1,941 (5.0%)
Food & Beverage$1,301 (3.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $31,671 | 10 | 81.1% |
| Unspecified | $4,150 | 6 | 10.6% |
| Travel and Lodging | $1,941 | 7 | 5.0% |
| Food and Beverage | $1,301 | 36 | 3.3% |
Payments by Type
General
$34,913
53 transactions
Research
$4,150
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $19,214 | 14 | $0 (2024) |
| TESARO, Inc. | $9,296 | 11 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $5,207 | 6 | $0 (2024) |
| ARRAY BIOPHARMA INC | $4,150 | 6 | $0 (2023) |
| Genentech USA, Inc. | $660.00 | 1 | $0 (2017) |
| Allergan Inc. | $157.60 | 14 | $0 (2018) |
| Roche Diagnostics Corporation | $125.00 | 1 | $0 (2022) |
| ABBVIE INC. | $99.68 | 1 | $0 (2024) |
| Clovis Oncology, Inc. | $91.64 | 1 | $0 (2018) |
| PFIZER INC. | $25.15 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,626 | 10 | GlaxoSmithKline, LLC. ($11,487) |
| 2023 | $8,574 | 10 | GlaxoSmithKline, LLC. ($7,726) |
| 2022 | $3,475 | 6 | ARRAY BIOPHARMA INC ($3,350) |
| 2021 | $12.70 | 1 | Eisai Inc. ($12.70) |
| 2020 | $3,450 | 1 | AstraZeneca Pharmaceuticals LP ($3,450) |
| 2019 | $8,994 | 10 | TESARO, Inc. ($8,981) |
| 2018 | $353.54 | 3 | TESARO, Inc. ($250.00) |
| 2017 | $2,578 | 18 | AstraZeneca Pharmaceuticals LP ($1,694) |
All Payment Transactions
59 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/18/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| Category: ONCOLOGY | ||||||
| 05/14/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.21 | General |
| 04/05/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Travel and Lodging | Cash or cash equivalent | $748.01 | General |
| Category: ONCOLOGY | ||||||
| 04/05/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Travel and Lodging | Cash or cash equivalent | $139.00 | General |
| Category: ONCOLOGY | ||||||
| 03/19/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 03/17/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $99.68 | General |
| Category: ONCOLOGY | ||||||
| 02/27/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $21.63 | General |
| 02/14/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $96.62 | General |
| 02/14/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $52.02 | General |
| 02/14/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $51.84 | General |
| 08/11/2023 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2023 | Ethicon US, LLC | Enseal (Device) | Food and Beverage | In-kind items and services | $23.74 | General |
| Category: Energy | ||||||
| 07/19/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $81.38 | General |
| 07/19/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $12.46 | General |
| 07/18/2023 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $278.12 | General |
| 06/27/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.26 | General |
| 05/18/2023 | ARRAY BIOPHARMA INC | MEKTOVI (Drug) | — | Cash or cash equivalent | $800.00 | Research |
| Study: THE MILO STUDY MEK INHIBITOR IN LOWGRADE SEROUS OVARIAN CANCER A MULTINATIONAL RANDOMIZED OPENLABEL PHASE 3 STUDY OF MEK162 VS PHYSICIANS CHOICE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR PERSISTENT LOWGRADE SEROUS CARCINOMAS OF THE OVARY FALLOPIAN TUBE OR PRIMARY PERITONEUM • Category: ONCOLOGY | ||||||
| 02/21/2023 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: ONCOLOGY | ||||||
| 01/25/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $122.56 | General |
| 01/25/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $31.65 | General |
| 11/23/2022 | ARRAY BIOPHARMA INC | MEKTOVI (Drug) | — | Cash or cash equivalent | $750.00 | Research |
| Study: THE MILO STUDY MEK INHIBITOR IN LOWGRADE SEROUS OVARIAN CANCER A MULTINATIONAL RANDOMIZED OPENLABEL PHASE 3 STUDY OF MEK162 VS PHYSICIANS CHOICE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR PERSISTENT LOWGRADE SEROUS CARCINOMAS OF THE OVARY FALLOPIAN TUBE OR PRIMARY PERITONEUM • Category: ONCOLOGY | ||||||
| 11/23/2022 | ARRAY BIOPHARMA INC | MEKTOVI (Drug) | — | Cash or cash equivalent | $250.00 | Research |
| Study: THE MILO STUDY MEK INHIBITOR IN LOWGRADE SEROUS OVARIAN CANCER A MULTINATIONAL RANDOMIZED OPENLABEL PHASE 3 STUDY OF MEK162 VS PHYSICIANS CHOICE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR PERSISTENT LOWGRADE SEROUS CARCINOMAS OF THE OVARY FALLOPIAN TUBE OR PRIMARY PERITONEUM • Category: ONCOLOGY | ||||||
| 09/28/2022 | ARRAY BIOPHARMA INC | MEKTOVI (Drug) | — | Cash or cash equivalent | $800.00 | Research |
| Study: THE MILO STUDY MEK INHIBITOR IN LOWGRADE SEROUS OVARIAN CANCER A MULTINATIONAL RANDOMIZED OPENLABEL PHASE 3 STUDY OF MEK162 VS PHYSICIANS CHOICE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR PERSISTENT LOWGRADE SEROUS CARCINOMAS OF THE OVARY FALLOPIAN TUBE OR PRIMARY PERITONEUM • Category: ONCOLOGY | ||||||
| 09/28/2022 | ARRAY BIOPHARMA INC | MEKTOVI (Drug) | — | Cash or cash equivalent | $800.00 | Research |
| Study: THE MILO STUDY MEK INHIBITOR IN LOWGRADE SEROUS OVARIAN CANCER A MULTINATIONAL RANDOMIZED OPENLABEL PHASE 3 STUDY OF MEK162 VS PHYSICIANS CHOICE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR PERSISTENT LOWGRADE SEROUS CARCINOMAS OF THE OVARY FALLOPIAN TUBE OR PRIMARY PERITONEUM • Category: ONCOLOGY | ||||||
| 09/28/2022 | ARRAY BIOPHARMA INC | MEKTOVI (Drug) | — | Cash or cash equivalent | $750.00 | Research |
| Study: THE MILO STUDY MEK INHIBITOR IN LOWGRADE SEROUS OVARIAN CANCER A MULTINATIONAL RANDOMIZED OPENLABEL PHASE 3 STUDY OF MEK162 VS PHYSICIANS CHOICE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR PERSISTENT LOWGRADE SEROUS CARCINOMAS OF THE OVARY FALLOPIAN TUBE OR PRIMARY PERITONEUM • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| THE MILO STUDY MEK INHIBITOR IN LOWGRADE SEROUS OVARIAN CANCER A MULTINATIONAL RANDOMIZED OPENLABEL PHASE 3 STUDY OF MEK162 VS PHYSICIANS CHOICE CHEMOTHERAPY IN PATIENTS WITH RECURRENT OR PERSISTENT LOWGRADE SEROUS CARCINOMAS OF THE OVARY FALLOPIAN TUBE OR PRIMARY PERITONEUM | ARRAY BIOPHARMA INC | $4,150 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 109 | 228 | $66,739 | $16,151 |
| 2022 | 4 | 113 | 262 | $79,671 | $19,239 |
| 2021 | 3 | 110 | 276 | $82,929 | $20,147 |
| 2020 | 2 | 51 | 124 | $30,472 | $7,771 |
Total Patients
383
Total Services
890
Medicare Billing
$63,308
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 40 | 120 | $26,280 | $8,522 | 32.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 32 | 64 | $26,308 | $4,661 | 17.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $5,616 | $1,554 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 25 | 32 | $8,535 | $1,414 | 16.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 34 | 133 | $29,127 | $9,839 | 33.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 22 | 61 | $23,859 | $4,414 | 18.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 18 | 18 | $11,592 | $1,923 | 16.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $5,148 | $1,598 | 31.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 28 | 39 | $9,945 | $1,465 | 14.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 131 | $29,507 | $10,168 | 34.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 30 | 86 | $33,709 | $6,486 | 19.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 32 | 47 | $11,985 | $2,196 | 18.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 12 | 12 | $7,728 | $1,297 | 16.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 35 | 108 | $24,408 | $6,199 | 25.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 16 | 16 | $6,064 | $1,572 | 25.9% |
About Dr. John Farley, M.D
Dr. John Farley, M.D is a Obstetrics & Gynecology healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1427034578.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Farley, M.D has received a total of $39,063 in payments from pharmaceutical and medical device companies, with $11,626 received in 2024. These payments were reported across 59 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($31,671).
As a Medicare-enrolled provider, Farley has provided services to 383 Medicare beneficiaries, totaling 890 services with total Medicare billing of $63,308. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Obstetrics & Gynecology
- Other Specialties Gynecologic Oncology
- Location Phoenix, AZ
- Active Since 12/21/2005
- Last Updated 12/05/2024
- Taxonomy Code 207V00000X
- Entity Type Individual
- NPI Number 1427034578
Products in Payments
- JEMPERLI (Biological) $18,487
- ZEJULA (Drug) $9,046
- MEKTOVI (Drug) $4,150
- LYNPARZA (Drug) $3,533
- Avastin (Biological) $660.00
- ELAHERE (Drug) $99.68
- VRAYLAR (Drug) $47.74
- LINZESS (Drug) $30.88
- BYSTOLIC (Drug) $30.54
- NAMZARIC (Drug) $30.39
- PREVNAR - 13 (Biological) $25.15
- Enseal (Device) $23.74
- VIBERZI (Drug) $18.05
- Dayvigo (Drug) $12.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in Phoenix
Lyndsay Willmott, Md, MD
Obstetrics & Gynecology — Payments: $430,201
Obstetrics & Gynecology $430,201
Steven Nelson, Md, MD
Obstetrics & Gynecology — Payments: $174,102
Obstetrics & Gynecology $174,102
Dr. Bj Ho, D.o, D.O
Obstetrics & Gynecology — Payments: $136,178
Obstetrics & Gynecology $136,178
Dr. Debra Wickman, Md, MD
Obstetrics & Gynecology — Payments: $107,602
Obstetrics & Gynecology $107,602
Heather Zechman, Md, MD
Obstetrics & Gynecology — Payments: $90,217
Obstetrics & Gynecology $90,217
Dr. David Glassman, D.o, D.O
Obstetrics & Gynecology — Payments: $79,552
Obstetrics & Gynecology $79,552